Clinical Trial Update: An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nivolumab plus brentuximab vedotin for non-Hodgkin lymphoma completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Hodgkin's Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-07